- Home
- BLLN vs ARWR Comparison
BLLN vs ARWR Comparison
Compare BLLN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLLN | ARWR |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.6B |
| IPO Year | 2025 | 1993 |
Fundamental Metrics
Financial Performance| Metric | BLLN | ARWR |
|---|---|---|
| Price | $100.35 | $65.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $138.67 | $56.00 |
| AVG Volume (30 Days) | 270.6K | ★ 2.7M |
| Earning Date | 12-09-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $209,032,000.00 | ★ $829,448,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 112.72 | ★ 23258.15 |
| 52 Week Low | $88.00 | $9.57 |
| 52 Week High | $138.70 | $66.23 |
Technical Indicators
Market Signals| Indicator | BLLN | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 80.46 |
| Support Level | N/A | $37.06 |
| Resistance Level | N/A | $59.15 |
| Average True Range (ATR) | 0.00 | 4.37 |
| MACD | 0.00 | 2.17 |
| Stochastic Oscillator | 0.00 | 97.27 |
Price Performance
Historical ComparisonAbout BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.